睡茄提取物(Withania somnifera Extract) - 药物靶点：SLC8A3_在研适应症：肌萎缩侧索硬化，阿尔茨海默症_专利_临床

概要

基本信息

药物类型

中药

别名

Withania somnifera roots extract

靶点

SLC8A3

作用机制

SLC8A3 agonists(solute carrier family 8 member A3 agonists)

治疗领域

神经系统疾病内分泌与代谢疾病其他疾病

在研适应症

肌萎缩侧索硬化阿尔茨海默症

非在研适应症

广泛性焦虑障碍精神分裂症

原研机构-

在研机构

华中科技大学

WellSpring School of Allied Health

Sunnybrook Health Sciences Centre

非在研机构

University of California, Los Angeles

Natreon, Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

登录后查看时间轴

关联

4

项与睡茄提取物相关的临床试验

CTRI/2024/03/064007 / Completed临床3期IIT

Effects of Eight weeks Supplementation of Withania Somnifera on Biochemical and Physical Components Among Football Players - Nil

开始日期2024-03-24

申办/合作机构-

NCT05031351 / Recruiting临床2期IIT

Nuclear Factor Kappa Beta Inhibition in Patients With Amyotrophic Lateral Sclerosis: A Phase II Randomized Placebo Controlled Trial

This is a Phase II, single centre, randomized, parallel, double blind, placebo-controlled clinical trial to determine the safety of Withania somnifera in participants with Amyotrophic Lateral Sclerosis (ALS).

开始日期2021-10-19

申办/合作机构

Sunnybrook Health Sciences Centre

NCT03437668 / Terminated临床2/3期IIT

Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia

To determine whether a standardized extract of Withania somnifera will reduce psychopathology scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress scores on the Perceived Stress Scale (PSS).

开始日期2018-12-01

申办/合作机构

University of Maryland

[+1]

100 项与睡茄提取物相关的临床结果

登录后查看更多信息

100 项与睡茄提取物相关的转化医学

登录后查看更多信息

100 项与睡茄提取物相关的专利（医药）

登录后查看更多信息

6

项与睡茄提取物相关的文献（医药）

2021-12-28·Cureus

Withania somnifera as an Adjunctive Treatment for Refractory Restless Legs Syndrome in Parkinson’s Disease: A Case Report

作者: Chaudhari, Kaustubh S ; Tiwari, Rakesh R ; Singh, Harish B ; Joshi, Swati V ; Chaudhari, Saurabh S

Non-motor symptoms of Parkinson's disease (PD), such as insomnia and restless legs syndrome (RLS), tend to worsen and become refractory as neurodegeneration progresses. We report the case of a 72-year-old female with a six-year history of PD and two-and-half-year history of insomnia and refractory RLS. We added a neuroprotective agent, Withania somnifera, to the existing treatment regimen for her insomnia. Besides the partial remission of her insomnia and motor symptoms of PD, there was a complete reversal of the RLS symptoms. Withania somnifera has been shown to improve PD symptoms by preventing oxidative damage of the nigrostriatal dopaminergic neurons and improving dopamine levels in the midbrain and corpus striatum. Our case provides the first-time evidence where Withania somnifera added for insomnia caused a complete remission of refractory RLS, possibly due to its anti-apoptotic and pro-dopaminergic actions. Withania somnifera could prove beneficial in cases where the disease advances but further addition of dopamine agonists for refractory RLS is not possible due to the risk of dopamine augmentation.

2019-06-01·Clinical Immunology3区 · 医学

Effect of Withania somnifer on CD38 expression on CD8+ T lymphocytes among patients of HIV infection

3区 · 医学

Article

作者: Tyagi, Sonu ; Das, Bimal Kumar ; Singh, Ravinder ; Maurya, Shesh Prakash

CD38 on CD8 + T cells is considered a reliable marker of HIV disease progression. Withania somnifer, a traditional ayurvedic medicine, has Th1 immunomodulatory properties. PBMCs from 38 HIV patients were exposed to Withania somnifer root extract at standardized concentration. An overall decline in the percentage of CD38 expressing CD8 + T lymphocytes was observed, though the statistical significance was varied with different categories of HIV patients. Withania somnifer could have promising impact on HIV disease and therefore warrants a further study on larger parameters.

2018-09-01·Andrologia4区 · 医学

Comparative evaluation of the effects ofWithania somniferawith pentoxifylline on the sperm parameters in idiopathic male infertility: A triple-blind randomised clinical trial

4区 · 医学

Article

作者: Fazljou, S. M. B. ; Nazemiyeh, H. ; Zomorrodi, A. ; Ahmadi AsrBadr, Y. ; Moini Jazani, A. ; Nejatbakhsh, F. ; Sadeghi Bazargani, H. ; Nasimi Doost Azgomi, R.

In this triple-blind randomised clinical trial, we compared the effects of Withania somnifera and pentoxifylline on the sperm parameters in idiopathic male infertility. One hundred infertile male patients were randomly allocated into either W. somnifera or pentoxifylline groups. Patients in the herbal group received six capsules containing 5 g/daily of W. somnifera root, and subjects in the pentoxifylline group received six capsules containing 800 mg/daily of pentoxifylline and placebo for 90 days. Sperm parameters were analysed at the beginning and end of the study. W. somnifera increased mean sperm count (12.5%) and progressive motility (21.42%) and improved sperm morphology (25.56%) compared to the baseline (p = .04, p = .001 and p = .000 respectively). Moreover, pentoxifylline increased mean semen volume (16.46%), progressive motility (25.97%) and improved sperm morphology (13.28%) versus the baseline (p = .02, p = .003 and p = .01 respectively). Intergroup comparison showed no significant differences between the two groups regarding semen volume (p = .11), sperm count (p = .09), morphology (p = .12) and progressive motility (p = .77) after treatment. No major complication was reported in either of the two groups. W. somnifera, a traditional medicine remedy, improves sperms parameters in idiopathic male infertility without causing adverse effects. Therefore, this medication can be considered to be an alternative to pentoxifylline in this regard.

100 项与睡茄提取物相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌萎缩侧索硬化	临床2期	加拿大	Sunnybrook Health Sciences Centre	2021-10-19
精神分裂症	临床1期	美国	University of California, Los Angeles	2018-12-01
阿尔茨海默症	临床前	中国	华中科技大学	2022-12-20
阿尔茨海默症	临床前	美国	WellSpring School of Allied Health	2022-12-20
广泛性焦虑障碍	药物发现	印度	Natreon, Inc.	2011-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03437668 (CTgov)	临床2/3期	精神分裂症	47	WSE (Withania Somnifera Extract (WSE))	鹹觸觸鹽廠築衊繭憲願(襯艱顧繭獵積築鏇顧構) = 鹽顧鏇遞繭壓憲蓋顧顧鏇糧積衊獵顧糧糧鹹壓 (襯獵鏇憲醖餘齋蓋襯簾, 膚襯築糧糧艱遞鬱糧壓 ~ 衊壓構壓膚鹹齋鹽範顧) 更多	-	2024-10-08
				Placebo Oral Tablet (Placebo Tablets)	鹹觸觸鹽廠築衊繭憲願(襯艱顧繭獵積築鏇顧構) = 築獵窪艱網構鹹淵艱鹽鏇糧積衊獵顧糧糧鹹壓 (襯獵鏇憲醖餘齋蓋襯簾, 夢鹹遞獵繭鹽窪襯鏇遞 ~ 蓋壓鹹壓鑰醖淵衊壓簾) 更多